1. Show article details.

    BRIEF-Bluebird Bio Appoints Denice Torres To Board Of Directors

    Reuters – 7:24 AM ET 08/11/2020

    bluebird bio Inc: * BLUEBIRD BIO APPOINTS DENICE TORRES TO BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

  2. Show article details.

    bluebird bio Appoints Denice Torres to Board of Directors

    Business Wire – 7:01 AM ET 08/11/2020

    bluebird bio, Inc. today announced that it has appointed Denice Torres to its Board of Directors. “We’re excited to welcome Denice to the Board to help guide bluebird as we reach the next stage in our evolution,” said Nick Leschly, chief bluebird.

  3. Show article details.

    BRIEF-Bluebird Bio Reports Second Quarter 2020 Financial Results And Recent Operational Progress

    Reuters – 5:50 PM ET 08/05/2020

    bluebird bio Inc: * BLUEBIRD BIO REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND RECENT OPERATIONAL PROGRESS. * Q2 REVENUE $198.9 MILLION VERSUS $13.3 MILLION. * Q2 REVENUE ESTIMATE $66.7 MILLION -- REFINITIV IBES DATA. * QTRLY LOSS PER SHARE $0.36 Source text for Eikon: Further company coverage:

  4. Show article details.

    bluebird bio Reports Second Quarter 2020 Financial Results and Recent Operational Progress

    Business Wire – 4:10 PM ET 08/05/2020

    – First sickle cell patient treated with drug product manufactured with suspension-based lentiviral vector in HGB-206 – – Elivaldogene autotemcel in cerebral adrenoleukodystrophy granted accelerated assessment of Marketing Authorization Application from EMA – – In partnership with Bristol-Myers Squibb (BMY), completed submission of Biologics License Application to FDA for ide-cel – – ...

  5. Show article details.

    Advancing Early-detection Measures Seek to Curb Cancer's Progression

    PR Newswire – 9:00 AM ET 07/31/2020

    NEW YORK, July 31, 2020 According to the World Health Organization, cancer is the leading cause of mortality globally, accounting for approximately 9.6 million deaths in 2018. The three key categories of drugs used for cancer, based on their mechanism of action, are cytotoxic drugs, targeted drugs, and hormonal drugs.

  6. Show article details.

    bluebird bio Announces August Investor Event

    Business Wire – 8:00 AM ET 07/31/2020

    bluebird bio, Inc. today announced members of the management team will participate in the Canaccord Genuity 40th Annual Growth Conference, Wednesday, August 12, at 10:30 a.m. ET.

  7. Show article details.

    BRIEF-Bristol Myers Squibb And Bluebird Bio Announce Submission Of Biologics License Application (BLA) To FDA For Idecabtagene Vicleucel

    Reuters – 6:16 PM ET 07/29/2020

    Bristol-Myers Squibb Co (BMY): * BRISTOL MYERS SQUIBB AND BLUEBIRD BIO ANNOUNCE SUBMISSION OF BIOLOGICS LICENSE APPLICATION TO FDA FOR IDECABTAGENE VICLEUCEL FOR ADULTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA. * BRISTOL-MYERS SQUIBB (BMY) - COMPANIES ARE COMMITTED TO WORKING WITH FDA TO RAPIDLY ADVANCE IDE-CEL THROUGH REGULATORY REVIEW PROCESS Source text for Eikon: Further company coverage:

  8. Show article details.

    Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) to FDA for Idecabtagene Vicleucel (Ide-cel, bb2121) for Adults with Relapsed and Refractory Multiple Myeloma

    Business Wire – 4:16 PM ET 07/29/2020

    BLA submission based on results from pivotal Phase 2 KarMMa study evaluating ide-cel in heavily pre-treated patient population Companies are committed to working with the FDA to rapidly advance ide-cel through the regulatory review process PRINCETON, N.J., & CAMBRIDGE, Mass.

  9. Show article details.

    Majority of Evaluable Patients Across Genotypes Achieve Transfusion Independence and Maintain It with Near-Normal Hemoglobin Levels in Phase 3 Studies of betibeglogene autotemcel (LentiGlobin™ for β-thalassemia) Gene Therapy Presented at EHA Congress

    Business Wire – 5:30 AM ET 06/12/2020

    89% of evaluable patients with transfusion-dependent β-thalassemia who do not have a β0/β0 genotype achieved transfusion independence with 11.9 g/dL median weighted average total hemoglobin level in HGB-207 Data from exploratory analyses of HGB-207 show improved markers of blood cell production and bone marrow function in patients who achieved transfusion independence 85% of patients with a ...

  10. Show article details.

    New Data Show Near Elimination of Sickle Cell Disease-Related Vaso-Occlusive Crises and Acute Chest Syndrome in Phase 1/2 Clinical Study of bluebird bio’s LentiGlobin™ Gene Therapy for Sickle Cell Disease at 25th EHA Congress

    Business Wire – 5:30 AM ET 06/12/2020

    99.5% reduction in annualized rate of vaso-occlusive crises and acute chest syndrome in Group C patients with a history of VOCs and ACS who had at least six months follow-up At up to 24 months, no reports of serious VOC or ACS in Group C patients with at least six months follow-up Group C patients with at least six months follow-up continue to produce consistent levels of gene therapy-derived ...

  11. Show article details.

    bluebird bio Announces That Its 2020 Annual Meeting of Stockholders Will Be Held in Virtual Format

    Business Wire – 4:05 PM ET 06/03/2020

    bluebird bio, Inc. today announced that, due to the public health and safety concerns related to the novel coronavirus pandemic, to support the health and well-being of its directors, employees and stockholders, the location of the Company’s 2020 Annual Meeting of Stockholders has been changed to a virtual format only.

  12. Show article details.

    bluebird bio Announces Live Webcast of EHA Data Review and June Investor Events

    Business Wire – 8:00 AM ET 05/28/2020

    bluebird bio, Inc. today announced that the company will host a live webcast to review new data presented at the European Hematology Association Annual Meeting on Friday, June 12 at 8:00 am ET. Investors may listen to the call on June 12, 2020 at 8:00 am ET by dialing 825-4408 from locations in the United States or +1 625-3227 from outside the United States.

  13. Show article details.

    BRIEF-Bluebird Bio Announces Pricing Of Public Offering Of Common Stock

    Reuters – 9:37 PM ET 05/18/2020

    bluebird bio Inc: * BLUEBIRD BIO ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK. * SAYS PUBLIC OFFERING OF 9.09 MILLION COMMON SHARES PRICED AT $55.00PER SHARE Source text for Eikon: Further company coverage:

  14. Show article details.

    bluebird bio Announces Pricing of Public Offering of Common Stock

    Business Wire – 9:32 PM ET 05/18/2020

    bluebird bio, Inc. today announced the pricing of an underwritten public offering of 9,090,910 shares of its common stock at a public offering price of $55.00 per share, before underwriting discounts.

  15. Show article details.

    BRIEF-Bluebird Bio Announces Proposed Public Offering Of Common Stock

    Reuters – 7:14 AM ET 05/18/2020

    bluebird bio Inc: * BLUEBIRD BIO ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK. * BLUEBIRD BIO (BLUE) - COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $400 MILLION OF STOCK Source text for Eikon: Further company coverage:

  16. Show article details.

    bluebird bio Announces Proposed Public Offering of Common Stock

    Business Wire – 7:00 AM ET 05/18/2020

    bluebird bio, Inc. today announced that it has commenced an underwritten public offering of $400 million of its common stock. bluebird bio also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent of the shares of common stock offered in the public offering.

Page:

Today's and Upcoming Events

  • Oct
    29

    BLUE to announce Q3 earnings (Unconfirmed)

Past Events (last 90 days)

  • Aug
    05

    BLUE announced Q2 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.